ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore immune tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT is working on a functional T-cell test to facilitate the diagnosis and monitoring of immune tolerance in patients undergoing peptide-based therapy. Through its innovative approach, the company seeks to enhance the management of celiac disease and potentially other autoimmune conditions.
Melinta Therapeutics
Post in 2015
Melinta Therapeutics is a pharmaceutical company dedicated to discovering, developing, and commercializing novel antibiotics to combat drug-resistant infections. Its portfolio includes Baxdela, Vabomere, Orbactiv, and Minocin, treating various bacterial infectious diseases. The company's mission is driven by the urgent need for new therapies against antibiotic-resistant pathogens.
ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore immune tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT is working on a functional T-cell test to facilitate the diagnosis and monitoring of immune tolerance in patients undergoing peptide-based therapy. Through its innovative approach, the company seeks to enhance the management of celiac disease and potentially other autoimmune conditions.
Melinta Therapeutics
Post in 2014
Melinta Therapeutics is a pharmaceutical company dedicated to discovering, developing, and commercializing novel antibiotics to combat drug-resistant infections. Its portfolio includes Baxdela, Vabomere, Orbactiv, and Minocin, treating various bacterial infectious diseases. The company's mission is driven by the urgent need for new therapies against antibiotic-resistant pathogens.
Pearl Therapeutics
Venture Round in 2013
Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.
Melinta Therapeutics
Post in 2012
Melinta Therapeutics is a pharmaceutical company dedicated to discovering, developing, and commercializing novel antibiotics to combat drug-resistant infections. Its portfolio includes Baxdela, Vabomere, Orbactiv, and Minocin, treating various bacterial infectious diseases. The company's mission is driven by the urgent need for new therapies against antibiotic-resistant pathogens.
Pearl Therapeutics
Series D in 2012
Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.
Pearl Therapeutics
Private Equity Round in 2012
Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.
ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore immune tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT is working on a functional T-cell test to facilitate the diagnosis and monitoring of immune tolerance in patients undergoing peptide-based therapy. Through its innovative approach, the company seeks to enhance the management of celiac disease and potentially other autoimmune conditions.
Pearl Therapeutics
Series C in 2010
Pearl Therapeutics develops innovative combination therapies for treating prevalent respiratory diseases like COPD, focusing on improving accessibility via familiar inhalers. Led by experienced experts, the company aims to enhance clinical outcomes by offering alternatives that surpass existing treatments' safety and efficacy.